Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX and XELIRI Alternation in Advanced Colorectal Cancer
NCT03511170Phase 2Unknown
- Sponsor
- Harbin Medical University
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan, capecitabine in colorectal cancer (CRC), sponsored by Harbin Medical University. Status: unknown.
02
Drugs
oxaliplatinirinotecancapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03511170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511170.